Needham analyst Gil Blum maintained a Buy rating on Artiva Biotherapeutics, Inc. (ARTV – Research Report) today and set a price target of $23.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Gil Blum has given his Buy rating due to a combination of factors including the strategic decision by Artiva Biotherapeutics, Inc. to delay the initial AID clinical data release to the second half of 2025. This delay is intended to provide a more comprehensive dataset, offering investors a clearer understanding of the company’s lead indication and overall value proposition. The decision is supported by the fact that study enrollment rates remain competitive with industry peers.
Additionally, Artiva is expanding its research efforts by initiating a basket study for AlloNK across various autoimmune diseases beyond lupus, such as rheumatoid arthritis, Sjogren’s syndrome, idiopathic inflammatory myopathies, and systemic sclerosis. Furthermore, recent abstract results presented at the ASGCT meeting indicate promising long-term efficacy and safety for AlloNK in patients with relapsed or refractory non-Hodgkin’s lymphoma. The company’s strong financial position, with approximately $166 million at the end of the first quarter of 2025, also supports the Buy rating, as it extends their cash runway guidance.